Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech ...

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech ...

Chemomab is a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need. Based on the unique role of the soluble protein CCL24 in ...

A remarkable aspect of this technology is its ability to project entirely different images depending on both the wavelength (color) and spin (polarization direction) of light. For example, ...

Investing.com -- HSBC downgraded several major biotech names this week, citing macroeconomic sensitivities, tariff risks, and growing pressure from regulatory changes. Most notably, the bank ...

(KRON) — The future of one biotech company on the Peninsula is drastically changing. Unity Biotechnology is laying off its entire workforce, the company announced Monday in a press release.

Unity Biotechnology, a Bay Area company that once won high-profile backers and a $700 million valuation for its research into aging, is now laying off every one of its remaining employees.

Vinay Prasad's appointment as CBER director has caused biotech stocks to fall due to concerns over potential regulatory changes. Prasad's history of criticizing FDA decisions suggests possible ...

China’s WuXi AppTec, which a US legislative commission called the “Huawei equivalent for biotechnology”, has reported a surge in US business despite increased scrutiny from Washington ...

Biotech stocks are in the eye of the storm as the world recovers from the global pandemic. Government institutions and professional traders are banking on biotech stocks to continually develop a ...

Sanofi has scrapped its collaboration with IGM Biosciences, eliminating the biotech’s last program in the process. IGM responded by laying off 80% of its staff and closing most of its lab and ...

Anti-aging biotech NewLimit plans to push a liver-rejuvenating mRNA medicine into the clinic with the aid of a $130 million series B fundraising round. The round was led by Kleiner Perkins ...